DFTX
Definium Therapeutics, Inc.
36.20$
-1.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
Definium Therapeutics, Inc. (DFTX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -53 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q4 18 | Q1 19 | Q2 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.2 | -0.3 | -0.1 | -0.2 | -0.2 | -0.3 | -0.1 | -0.2 | 0.1 | -0.3 | 0.0 | -5.1 | -5.6 | -5.8 | -7.1 | -10 | -11 | -17 | -14 | -13 | -15 | -9.3 | -13 | -13 | -14 | -17 | -21 | -17 | -20 | -17 | -25 | -29 | -30 | -30 | -42 | -43 | -53 | -167 | |
| – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | – | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | -0.4 | 0.3 | 0.8 | 0.8 | -5.1 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.5 | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 | -0.6 | 0.0 | |
| – | – | – | – | – | – | – | – | – | – | – | – | -2.1 | 4.0 | 5.1 | 1.3 | 33 | 4.1 | 11 | 3.8 | 4.3 | 4.3 | 1.4 | 3.8 | 3.8 | 4.2 | 3.7 | 3.7 | 5.4 | 3.8 | 3.4 | 3.4 | 5.3 | 5.8 | 11 | 7.1 | 9.6 | 34 | |
| -0.1 | 0.0 | 0.1 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | -0.1 | 0.1 | -0.2 | -1.1 | 1.1 | 2.2 | 2.2 | 0.3 | -4.5 | -1.2 | 1.0 | -3.3 | 0.6 | -2.1 | 1.7 | 9.5 | -1.1 | -3.8 | -0.7 | -3.5 | 4.1 | -0.2 | -2.5 | 8.1 | 8.1 | -4.5 | 5.4 | 6.3 | 15 | |
| 0.3 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| -0.6 | -1.3 | -1.8 | -0.1 | 0.2 | 0.2 | 0.2 | -0.1 | -0.1 | 0.0 | 0.0 | – | – | – | – | -0.3 | -0.1 | 0.0 | 0.2 | – | – | – | – | – | – | – | – | – | – | – | – | -162 | -40 | 15 | 38 | 42 | -317 | -222 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -0.4 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.1 | 1.0 | 0.0 | 20 | 0.4 | 0.0 | – | – | – | |
| 0.7 | 1.7 | 1.8 | 0.2 | 0.0 | 0.0 | 0.0 | 0.3 | 0.3 | 0.0 | 0.0 | 19 | 9.1 | 0.0 | 69 | 90 | 7.9 | 0.8 | 0.1 | -0.2 | 0.6 | 58 | 0.4 | 0.6 | 1.3 | 17 | 2.6 | 169 | 11 | 69 | 3.8 | 1.0 | 20 | 0.7 | 247 | 5.3 | 762 | 1,015 | |
| – | – | – | – | – | – | – | – | – | – | – | 20 | 3.6 | -5.8 | 62 | 80 | -2.9 | -11 | -12 | -13 | -15 | 49 | -12 | -13 | -13 | 0.8 | -18 | 153 | -9.2 | 52 | -22 | -191 | -49 | -13 | 238 | 4.7 | 393 | 622 | |
| -0.5 | -0.2 | -0.1 | -0.1 | -0.2 | -0.2 | -0.1 | -0.2 | 0.1 | -0.3 | 0.0 | -5.1 | -5.6 | -5.8 | -7.1 | -10 | -11 | -17 | -14 | -13 | -15 | -9.3 | -13 | -13 | -14 | -17 | -21 | -17 | -20 | -17 | -25 | -29 | -30 | -30 | -42 | -43 | -53 | -167 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.